News

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

Dual therapy may slow the progression of condition.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

According to the company, its latest laser recently received FDA clearance and CE mark approval.

According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.

Medical, surgical management can be important tools.

While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

SLT shows promise as treatment for millions of Africans with glaucoma.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

The investigative team wanted to provide physicians with reference guidelines to aid in the prevention and control of myopia.

Macular hole closure results from this novel treatment.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.

In a recent update, the CDC has noted an additional death, bringing the death toll up to 4, with numerous counts of vision loss across the US.

Data demonstrate a reduction in the loss of retinal pigmented epithelial and photoreceptor cells.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

According to the company, the Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial. Up to 24 subjects will receive a single periocular injection and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, and efficacy measured by best corrected visual acuity.

According to the company, the DIAMOND trial in diabetic macular edema with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significance.

Study: AO retinal imaging has the potential to become a sensitive marker for disease.

The company noted tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score or in improvement in Eye Dryness Score assessed at week 8 in subjects with dry eye disease, compared to vehicle. However, tanfanercept did demonstrate a highly statistically significant improvement on one of the secondary outcome measures, Schirmer testing of tear volume.

Ophthalmology Times reached out to members of its editorial advisory board along with ophthalmologists who specialize in dry eye for their comments on what this approval means for their patients with dry eye.

The number of cases continues to rise throughout the world

According to the companies, MIEBO is the first and only prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.